



Annexure - I

Jeevan Scientific Technology Limited
a symbol of quality and diverse solutions

Ref: JSTL/BOD/BSE/2022-23/Aug22

Date: August 12, 2022

**To,
The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001
(BSE Scrip Code: 538837)**

Dear Sir/Madam,

Sub: Copy of Unaudited Financial Results for the Quarter Ended 30th June, 2022.

Ref: Scrip code: 538837

Unit: Jeevan Scientific Technology Limited

Please find enclosed herewith a Copy of Unaudited Financial Results for the Quarter Ended 30th June, 2022 which were taken on record by the Board of Directors at their Meeting held on 12th August, 2022.

This is for your information and records,

Thanking you,

Yours truly,

For JEEVAN SCIENTIFIC TECHNOLOGY LIMITED


**K. KRISHNA KISHORE
VICE CHAIRMAN & MANAGING DIRECTOR
(DIN: 00876539)**



Encl. As above

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED
Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2022

Rupees in Lakhs

Sl.No	Particulars	Quarter Ended			Year Ended	
		30-06-2022 Unaudited	31-03-2022 Audited	30-06-2021 Unaudited	31-03-2022 Audited	
1	Income					
	(a) Revenue From Operations	1032.79	1065.08	1376.04	5655.49	
	(b) Other Income	21.46	511.62	7.94	590.98	
	Total Income	1,054.25	1,576.70	1,383.98	6,246.47	
2	Expenses					
	(a) Cost of Material Consumed	40.92	51.59	83.69	369.43	
	(b) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	54.65	125.30	(14.79)	369.93	
	(c) Employee benefit expense	301.85	528.81	331.94	1502.38	
	(d) Finance Cost	27.19	19.46	26.74	95.83	
	(e) Depreciation and Amortisation expense	105.3	71.45	99.23	367.93	
	(f) Other Expenses	506.89	417.36	431.91	1706.07	
	Total Expenses	1,036.80	1,213.97	958.72	4,411.57	
3	Profit before exceptional items and Tax	17.45	362.73	425.26	1,834.90	
4	Add(+)/Less(-) Exceptional items	-	-	-	-	
5	Profit/ (Loss) before Tax	17.45	362.73	425.26	1,834.90	
6	Tax Expenses	(20.86)	147.40	138.19	608.59	
7	Profit(Loss) for the Period from Continuing Operations	38.31	215.33	287.07	1,226.31	
8	Profit(Loss) from Discontinuing Operations	-	-	-	-	
9	Tax Expenses on discontinuing Operations	-	-	-	-	

Mamidi



[Signature]

Sl.No	Particulars	Quarter Ended				Year Ended	
		30-06-2022	31-03-2022	30-06-2021	31-03-2022	Unaudited	Audited
10	Profit(Loss) from Discontinuing Operations after Tax					-	-
11	Profit(Loss) for the period	38.31	215.33	287.07	1,226.31		
12	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	0.87	18.66	0.63	21.03		
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-		
	B (i) Items that will be reclassified to profit or loss	-	-	-	-		
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-		
13	Total Comprehensive Income for the period	39.18	233.99	287.70	1,247.34		
14	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	1,530.15	1,530.15	1,530.15	1,530.15		
15	Other equity excluding revaluation reserve	-	-	-	3,528.16		
16	Earnings per Equity share (Face Value of Rs. 10/- each)						
	a) Basic (Amount in Rupees)	0.26	1.53	1.88	8.15		
	b) Diluted (Amount in Rupees)	0.25	1.53	1.88	8.15		

Notes to the Unaudited Financial Results

- The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015
- The Company has only one reportable segment namely "Clinical Research Services"
- Employee benefit expenses includes Rs. 53.76 Lakhs towards ESOP Scheme 2016 provided as per "Ind AS 102 - Share Based Payments"
- Q4 2021-22 Other Income includes Rs.404.22 Lakhs on Profit on Sale of Investments in subsidiary companies
- "The Company continues to monitor the impact of Covid-19 on its business, including its impact on customers, supply-chain, employees and logistics. Due care has been exercised, in concluding on significant accounting judgements and estimates, including in relation to recoverability of receivables, assessment of impairment of intangibles, investments, and inventory, based on the information available to date, while preparing the unaudited financial results for the quarter ended June 30, 2022".
- Figures for the previous periods have been rearranged/ reclassified wherever necessary to conform to the current period presentation
- The above Unaudited results have been reviewed by the Audit Committee at its meeting held on 12.08.2022 and approved by the Board of Directors of the Company on the same date. The results are also subjected to Limited Review by the Company's Statutory Auditors

Place: Hyderabad
Date: 12.08.2022

for Jeeyan Scientific Technology Limited
On behalf of the Board of Directors
K. Krishna Kishore
Vice Chairman & Managing Director

M. Sriharish Sasidhar
CFO





Ref: JSTL/BOD/BSE/2022-23/Aug22

Date: August 12, 2022

**To,
The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001
(BSE Scrip Code: 538837)**

Dear Sir/Madam,

Sub: Limited Review report of the Unaudited Financial Results for the Quarter
Ended 30th June, 2022.

Ref: Scrip code: 538837

Unit: Jeevan Scientific Technology Limited

We are herewith enclosing the Limited Review Report issued by our Statutory Auditors relating to the Unaudited Financial Results for the Quarter Ended 30th June, 2022 which were taken on record by the Board of Directors at their Meeting held on the 12th August, 2022.

This is for your information and records,

Thanking you,

Yours truly,

For JEEVAN SCIENTIFIC TECHNOLOGY LIMITED


**K. KRISHNA KISHORE
VICE CHAIRMAN & MANAGING DIRECTOR
(DIN: 00876539)**



Encl. As above



PAVULURI & Co.

CHARTERED ACCOUNTANTS


Plot No.48, Flat No.301,
MICASA, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639 / 2640
Email : mail@pavuluriandco.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF JEEVAN SCIENTIFIC TECHNOLOGY LIMITED


1. We have reviewed the accompanying Statement of Unaudited Financial Results of JEEVAN SCIENTIFIC TECHNOLOGY LIMITED ("the Company"), for the quarter ended June 30, 2022 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PAVULURI & CO.
Chartered Accountants
Firm Reg. No: 012194S


CA. N. Rajesh
Partner
M.No 223169

For PAVULURI & CO

Chartered Accountants
(Firm's Registration No. 012194S)



CA. N. RAJESH
Partner
(Membership No.223169)

UDIN: 22223169AOWVYP7936

Place: Hyderabad
Date: August 12, 2022

Branches :

Flat No : 301, Block C, Green City Towers, Green City Township, Near Export Apparel Park, Visakhapatnam - 530049.

D.No.54-20/7-1B, Plot No.10,Road No.2, Kanakadurga GAZZETTED OFFICERS colony, Gurunank Nagar, Vijayawada-520007. Ph: 0866-2545418